Ryan C - Search Results

1

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: ryan c. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.

2

Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.

Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Ryan CJ, et al. Urology. 2004 Jul;64(1):90-4. doi: 10.1016/j.urology.2004.03.006. Urology. 2004. PMID: 15245942 Clinical Trial.

3

Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".

Ryan CJ, Eisenberger M. Ryan CJ, et al. J Clin Oncol. 2005 Nov 10;23(32):8242-6. doi: 10.1200/JCO.2005.03.3092. J Clin Oncol. 2005. PMID: 16278479 Review.

4

Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.

Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Beekman KW, et al. Clin Genitourin Cancer. 2006 Mar;4(4):299-302. doi: 10.3816/CGC.2006.n.012. Clin Genitourin Cancer. 2006. PMID: 16729916

5

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Ryan CJ, et al. Clin Cancer Res. 2007 Apr 1;13(7):2030-7. doi: 10.1158/1078-0432.CCR-06-2344. Clin Cancer Res. 2007. PMID: 17404083 Clinical Trial.

6

Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference.

Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Kantoff PW, et al. J Urol. 2007 Sep;178(3 Pt 2):S5-8; quiz S4. doi: 10.1016/j.juro.2007.03.137. Epub 2007 Jul 20. J Urol. 2007. PMID: 17644118 No abstract available.

7

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.

Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI. Morris MJ, et al. Among authors: ryan c. J Urol. 2007 Dec;178(6):2378-83; discussion 2383-4. doi: 10.1016/j.juro.2007.08.015. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936848 Clinical Trial.

8

Novel therapeutic strategies in development for prostate cancer.

Harzstark AL, Ryan CJ. Harzstark AL, et al. Expert Opin Investig Drugs. 2008 Jan;17(1):13-22. doi: 10.1517/13543784.17.1.13. Expert Opin Investig Drugs. 2008. PMID: 18095915 Review.

9

Therapies in development for castrate-resistant prostate cancer.

Harzstark AL, Ryan CJ. Harzstark AL, et al. Expert Rev Anticancer Ther. 2008 Feb;8(2):259-68. doi: 10.1586/14737140.8.2.259. Expert Rev Anticancer Ther. 2008. PMID: 18279066 Review.

10

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Morris MJ, et al. Among authors: ryan c. Clin Genitourin Cancer. 2009 Jan;7(1):51-7. doi: 10.3816/CGC.2009.n.009. Clin Genitourin Cancer. 2009. PMID: 19213669 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,490 results

Search Page